Dalton Pharma Services has signed a drug development and manufacturing contract with Ramsey Lake Pharmaceutical Corp. (RLPC) to support toxicology studies for VR23, their novel β2-targeting proteasome inhibitor in development to treat cancer. The agreement includes the synthesis of VR23 by Dalton as well as the development of analytical testing methods and execution of a stability study. “We are excited to be moving our lead candidate VR23 into these critical toxicology studies with the help ...